WO2007039754A1 - Use of oligouronates for treating mucus hyperviscosity - Google Patents
Use of oligouronates for treating mucus hyperviscosity Download PDFInfo
- Publication number
- WO2007039754A1 WO2007039754A1 PCT/GB2006/003720 GB2006003720W WO2007039754A1 WO 2007039754 A1 WO2007039754 A1 WO 2007039754A1 GB 2006003720 W GB2006003720 W GB 2006003720W WO 2007039754 A1 WO2007039754 A1 WO 2007039754A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligouronate
- treatment
- physiologically tolerable
- mucus
- mucosal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Definitions
- This invention relates to a method of treatment of human or non-human animals, in particular mammals, with oligouronates to combat elevated mucosal viscosity, e.g. to enhance mucus clearance, especially from the respiratory tract such as in the case of COPD 's (chronic obstructive pulmonary diseases) , in particular the sinuses and the lungs, in particular in the treatment of cystic fibrosis (CF) , chronic obstructive pulmonary disease and sinusitis.
- COPD 's chronic obstructive pulmonary diseases
- CF cystic fibrosis
- Cystic fibrosis is the most common lethal genetic disease in European populations .
- the disease is caused by a mutation in the gene that codes for the cystic fibrosis transmembrane regulator (CFTR) , a chloride channel that is present in secretary and other cells in the body.
- CFTR cystic fibrosis transmembrane regulator
- the disease is characterized by the presence of thick, intractable mucus secretions in the body that can lead to lung disease, digestive problems and infertility.
- the normal pattern of mucociliary clearance in the lungs fails to clear the unduly viscous mucus which becomes colonized by microorganisms, which in turn increases mucus viscosity and may lead to chronic lung inflammation and obstruction. Lung disease is thus the biggest health problem for the majority of CF patients and is the major cause of death.
- Mucus is a normal secretion of the entire respiratory tract, including the lungs. Its primary function is as part of the mucociliary clearance system that keeps the lungs clean and protects against infection.
- the mucociliary clearance system has three main components: mucus; cilia; and the airway surface liquid.
- the epithelial surface thus comprises mucus secreting goblet cells and ciliated epithelial cells with an overlying layer of airway surface liquid and above that a layer of mucus, into which the tips of the cilia protrude.
- the mucus is a sticky gel material composed primarily of water (about 95% wt.) and mucins, gel forming molecules responsible for the physical properties of the mucus.
- the cilia are small hair-like projections from the surface of the epithelial cells, which beat rhythmically in the watery, non-viscous airway surface liquid with their tips immersed in the mucus layer.
- the mucus layer forms a sticky blanket on the lung surface that traps bacteria, viruses, inhaled particles, environmental pollutants and cell debris .
- the beating of the cilia serves to propel this mucus blanket and anything trapped in it towards the mouth and out of the lungs .
- the mucociliary clearance system functions effectively and the lungs are kept clean and free of infection. If the system is overwhelmed, there is a second line of defence - cough.
- the mucus is projected out of the lungs by the cough reflex.
- the mucus in the lung is thicker and more viscous than normal, and this thicker mucus is not so easily transported by the cilia. As a result the mucociliary clearance system is compromised and the lungs are more vulnerable to infection.
- the lungs of CF patients appear to be in a hyper- inflammatory state with a continual low level of inflammation and a heightened response to agents that normally cause inflammation. This is problematic as part of the response to inflammation is increased production of mucus. The increased mucus builds up if it is too thick to be cleared by the mucociliary clearance system or coughing, lung capacity is reduced and the exchange of oxygen across the mucosa is decreased.
- oligouronates i.e. multiply charged hydroxyl group carrying oligomers, in particular one containing two to thirty monomer residues .
- the invention provides a method of treatment of a human or non-human (e.g. mammalian) subject to combat mucosal hyperviscosity in the respiratory tract, e.g. to treat chronic obstructive pulmonary disease, sinusitis or cystic fibrosis patients, which method comprises application to a mucosal surface in said tract in said subject of an effective amount of a physiologically tolerable oligouronate polyol.
- a human or non-human (e.g. mammalian) subject to combat mucosal hyperviscosity in the respiratory tract, e.g. to treat chronic obstructive pulmonary disease, sinusitis or cystic fibrosis patients, which method comprises application to a mucosal surface in said tract in said subject of an effective amount of a physiologically tolerable oligouronate polyol.
- the invention provides the use of a physiologically tolerable oligouronate for the manufacture of a medicament for use in the treatment of ⁇ mucosal hyperviscosity in the respiratory tract.
- the application of the oligouronate may be by any means which delivers it to a mucus secreting, or mucus carrying surface in the patient's respiratory tract, e.g. the paranasal sinuses or more preferably the lungs.
- Introduction will typically be by inhalation, e.g. of liquid ⁇ droplets (for example an aerosol) or a powder.
- the counterions for the oligouronate may be any of the physiologically tolerable ions commonly used for charged drug substances, e.g. sodium, potassium, ammonium, chloride, mesylate, meglumine, etc. Ions which promote alginate gelation, e.g. group 2 metals, however will preferably not be used.
- the oligouronate may be a synthetic material, it is preferably a derivative, having a weight average molecular weight of less than 100000 Da, of a naturally occurring polysaccharide. It is preferably a 3- to 28- mer, in particular a 4- to 25-mer, especially a 6- to 22-mer, in particular an 8- to 15-mer, especially a 10- mer, e.g. having a molecular weight in the range 350 to 6000 Da especially 750 to 4500 Da. It may be a single compound or it may be a mixture of oligouronate compounds, e.g. of a range of degrees of polymerization. Moreover, the monomeric residues in the oligouronate, e.g.
- the monosaccharide groups may be the same or different and not all need carry electrically charged groups although it is preferred that the majority (e.g. at least 60%, preferably at least 80% more preferably at least 90%) do. It is preferred that a substantial majority, e.g. at least 80%, more preferably at least 90% of the charged groups have the same polarity.
- the ratio of hydroxyl groups to charged groups is preferably at least 2:1, more especially at least 3:1.
- Oligouronates are readily accessible from natural sources since many natural polysaccharides contain charged uronate residues, e.g. residues such as guluronic and galacturonic acid residues.
- Polysaccharide to oligosaccharide cleavage to produce oligosuronate useable according to the present invention may be performed using conventional polysaccharide lysis techniques such as enzymatic digestion and acid hydrolysis . Oligouronates may then be separated from the polysaccharide breakdown products chromatographycalIy using an ion exchange resin or by fractionated precipitation or solubilization.
- the oligouronates may also be chemically modified, including but not limited to modification to add charged groups (such as carboxylated or carboxymethylated glycans), and oligouronates modified to alter flexibility (e.g. by periodate oxidation)
- Suitable polysaccharides are discussed for example in "Handbook of Hydrocolloids” , Ed. Phillips and Williams, CRC, Boca Raton, Florida, USA, 2000.
- the use of alginates however is especially preferred as these naturally occur as block copolymers of manuronic (M) and guluronic (G) acids and G-block oligomers can readily be produced from alginate source materials .
- the oligouronate is preferably an oligoguluronic acid, or less preferably an oligogalacturonic acid.
- the guluronic acid content may if desired be increased by epimerization with mannouronan C-5 epimerases from A. vinelandii .
- Oligoguluronic acids suitable for use according to the invention may conveniently be produced by acid hydrolysis of alginic acid from Laminaria hyperborea, dissolution at neutral pH, addition of mineral acid to reduce the pH to 3.4 to precipitate the oligoguluronic acid, washing with weak acid, resuspension at neutral pH and freeze drying.
- the invention also provides a pharmaceutical composition, especially an inhalable composition, e.g. a solution, suspension, dispersion or powder, comprising a physiologically tolerable oligouronate together with a physiologically tolerable carrier or excipient, and preferably also a further physiologically tolerable mucosal viscosity reducing agent, e.g. a nucleic acid cleaving enzyme (e.g. a DNAse such as DNase I) , gelsolin, a thiol reducing agent, an acetylcysteine, sodium chloride, an uncharged low molecular weight polysaccharide (e.g.
- a nucleic acid cleaving enzyme e.g. a DNAse such as DNase I
- gelsolin e.g. a thiol reducing agent
- an acetylcysteine sodium chloride
- an uncharged low molecular weight polysaccharide e.g.
- the oligouronate may be administered typically in doses of 1 to lOOOOmg, especially 10 to lOOOmg for an adult human. The optimum does may readily be determined by routine dosage ranging experiments, optionally following initial investigation of an animal model, e.g. a dog model.
- compositions of the invention may be produced using conventional pharmaceutical carriers and excipients, e.g. solvents (such as water), osmolality modifiers, flavours, pH regulators, etc. They may contain additional active components, for example agents which serve to break down biopolymers not involved in the mucin matrix of the mucus (e.g. DNase, particularly rhDNase) , antibacterial agents, and antiinflammatories. Combination therapy using a such further agent and the oligouronate, administered separately or together is a particularly preferred aspect of the method of the invention. Such further agents may be used in their normal doses or even at lower doses, e.g. 50% of normal dose.
- solvents such as water
- osmolality modifiers such as water
- flavours such as water
- pH regulators e.g., etc.
- additional active components for example agents which serve to break down biopolymers not involved in the mucin matrix of the mucus (e.g. DNase, particularly rhDNase)
- the oligouronates are desirably administered as a spray, preferably an aerosol spray made from an aqueous solution or in the form of powders, e.g. of approximately nanometer to micrometer (e.g. 10 to 50000 nm) mode particle size by volume size.
- the invention provides a spray applicator comprising a reservoir and a droplet generator, said reservoir containing an aqueous solution of a physiologically tolerable oligouronate.
- a spray applicator comprising a reservoir and a droplet generator, said reservoir containing an aqueous solution of a physiologically tolerable oligouronate.
- Such spray applicators, and indeed the oligouroantes may be used in the treatment of sinus or nasal blockage or congestion resulting from the common cold or other reasons .
- Figures Ia to If are plots of complex modulus over time for a mucin-alginate gel and for the same gel dosed with dextran, polyethylene glycol, DNA, sodium galacturonate oligomer and sodium guluronate oligomer respectively;
- Figures 2 and 3 are bar charts showing the complex modulus (G*) and the phase angle of the same gels at the end of gelation as a percentage of the control;
- Figure 4 is a bar chart showing the flow stress of the same gels, again as a percentage of the control
- Figures 5a and 5b show the complex modulus G* for treated and untreated sputum samples from CF patients, Figure 5b showing G* as a percentage of control (the untreated sputum) ; Figures 5c to 5f show plots of G* over time;
- Figures 6a and 6b show the complex viscosity ( ⁇ *) for treated and untreated sputum samples, Figure 6b showing ⁇ * as a percentage of control;
- Figures 7a and 7b show the phase angle ⁇ for treated and untreated sputum samples .
- Figure 7b showing ⁇ as a percentage of control.
- Control gel consisted of 18mg/ml mucin + 0.6mg/ml alginate in 0.05M NaCl
- Test gels consisted of 18mg/ml mucin + 0.6mg/ml alginate + 4mg/ml test material in 0.05 M NaCl
- the complex modulus and phase angle of the gels at the end of the gelling period is plotted in Figures 2 and 3.
- the complex modulus is a measure of the total response or strength of the system and the phase angle concerns the balance between liquid like and solid like behaviour with a higher phase angle indicating greater liquid like behaviour.
- Sodium guluronate oligomers (G blocks) caused the greatest drop in G* and the greatest increase in the phase angle.
- a stress sweep was used to determine the stress needed to induce flow in the system. This is plotted in Figure 4 as a % of the stress needed to induce flow in the control gel. This gives an indication of how much the added material has weakened the gel matrix. G blocks (sodium guluronate oligomers) had the most pronounced effect on the flow stress followed by sodium galacturonate oligomers .
- Sputum samples were collected from cystic fibrosis patients with a positive diagnosis for Pseudomonas aeruginosa infection. The samples were gently stirred, divided into portions, frozen and stored at -40 0 C.
- the sputum samples were taken out from the freezer and placed in the fridge (4°C) one hour before testing, stirred on a magnetic stirrer for about 10 min and divided into 0.5 g portions. Testing media was added to all but one sample, the pure sputum sample. The resulting samples were:
- the mixed samples were then gently stirred for 1 min and subsequently placed into the fridge for 5 min before being transferred to the rheometer for testing.
- Figure 5a is bar chart showing the complex modulus (G*) for the sputum samples at the end of testing, after 60 min.
- Figure 5b is bar chart showing the same sputum samples as in figure 5a, but as percentage of the control (pure sputum) .
- Figure 5c to 5f are plots of complex modulus over time for the sputum samples A to D.
- Figure 6a is bar chart showing the complex viscosity ( ⁇ *) for the sputum samples at the end of testing, after 60 min.
- Figure 6b is bar chart showing the same sputum samples as in figure 6a, but as percentage of the control .
- Figure 7a is bar chart showing the phase angle ( ⁇ ) for the sputum samples at the end of testing, after 60 min.
- Figure 7b is bar chart showing the same sputum samples as in figure 3a, but as percentage of the control.
- a sterile aerosol spray administered by the aid of a nebuliser, is made from a liquid containing 3-10% of the sodium salt of a guluronic acid block with a purity of at least 75% guluronate and a degree of polymerisation between 5 and 20, and, if necessary, a surface active compound to stabilise the aerosol droplet size.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Dispersion Chemistry (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008534075A JP5313677B2 (en) | 2005-10-06 | 2006-10-06 | Use of oligouronic acid for the treatment of mucosal hyperviscosity |
CN2006800460615A CN101325973B (en) | 2005-10-06 | 2006-10-06 | Use of oligouronates for treating mucus hyperviscosity |
EA200801033A EA015436B1 (en) | 2005-10-06 | 2006-10-06 | Use of oligouronates for treating mucus hyperviscosity |
AU2006298544A AU2006298544B2 (en) | 2005-10-06 | 2006-10-06 | Use of oligouronates for treating mucus hyperviscosity |
DK06794671.5T DK1942938T3 (en) | 2005-10-06 | 2006-10-06 | Use of oligouronates to treat mucus hyperviscosity |
ES06794671T ES2390974T3 (en) | 2005-10-06 | 2006-10-06 | Use of oliguronates to treat hyperviscosity of mucus |
KR1020087010474A KR101144576B1 (en) | 2005-10-06 | 2006-10-06 | Use of oligouronate for treating mucus hyperviscosity |
US12/089,529 US8754063B2 (en) | 2005-10-06 | 2006-10-06 | Use of oligouronates for treating mucus hyperviscosity |
EP06794671A EP1942938B1 (en) | 2005-10-06 | 2006-10-06 | Use of oligouronates for treating mucus hyperviscosity |
CA2624568A CA2624568C (en) | 2005-10-06 | 2006-10-06 | Oligouronate treatment |
BRPI0616982A BRPI0616982B8 (en) | 2005-10-06 | 2006-10-06 | use of oligouronate, inhalable pharmaceutical composition and spray applicator |
HK09104636.3A HK1125855A1 (en) | 2005-10-06 | 2009-05-21 | Use of oligouronates for treating mucus hyperviscosity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0520375A GB2430881B (en) | 2005-10-06 | 2005-10-06 | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
GB0520375.7 | 2005-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007039754A1 true WO2007039754A1 (en) | 2007-04-12 |
Family
ID=35429950
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2006/003732 WO2007039760A2 (en) | 2005-10-06 | 2006-10-06 | Use of oligouronates for treating mucus hyperviscosity |
PCT/GB2006/003720 WO2007039754A1 (en) | 2005-10-06 | 2006-10-06 | Use of oligouronates for treating mucus hyperviscosity |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2006/003732 WO2007039760A2 (en) | 2005-10-06 | 2006-10-06 | Use of oligouronates for treating mucus hyperviscosity |
Country Status (15)
Country | Link |
---|---|
US (2) | US8673878B2 (en) |
EP (4) | EP3403657B1 (en) |
JP (1) | JP5313677B2 (en) |
KR (1) | KR101144576B1 (en) |
CN (1) | CN101325973B (en) |
AU (1) | AU2006298544B2 (en) |
BR (1) | BRPI0616982B8 (en) |
CA (1) | CA2624568C (en) |
DK (3) | DK1942938T3 (en) |
EA (1) | EA015436B1 (en) |
ES (3) | ES2390974T3 (en) |
GB (1) | GB2430881B (en) |
HK (1) | HK1125855A1 (en) |
PL (1) | PL3403657T3 (en) |
WO (2) | WO2007039760A2 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008125828A2 (en) * | 2007-04-12 | 2008-10-23 | Ntnu Technology Transfer As | Oligo-guluronate and galacturonate compositions |
WO2010139956A1 (en) | 2009-06-03 | 2010-12-09 | Algipharma Ipr As | Treatment of acinetobacter with alginate oligomers and antibiotics |
WO2010139958A1 (en) | 2009-06-03 | 2010-12-09 | Algipharma Ipr As | Anti-microbial alginate oligomers |
WO2010139959A2 (en) | 2009-06-03 | 2010-12-09 | Algipharma Ipr As | Alginate oligomers for the inhibition of microbial adherence to surfaces |
WO2013038197A1 (en) | 2011-09-15 | 2013-03-21 | Algipharma As | Use of alginate oligomers to enhance the effects of antifungal agents |
US8529890B2 (en) | 2009-03-23 | 2013-09-10 | Ntnu Technology Transfer As | Composition for the administration of polymeric drugs |
US8673878B2 (en) | 2005-10-06 | 2014-03-18 | Ntnu Technology Transfer As | Mucosal treatment |
US8680072B2 (en) | 2007-11-27 | 2014-03-25 | Algipharma As | Use of alginate oligomers in combating biofilms |
US8987215B2 (en) | 2009-03-23 | 2015-03-24 | Ntnu Technology Transfer As | Composition for use in gene therapy |
WO2015128495A1 (en) * | 2014-02-28 | 2015-09-03 | Algipharma As | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function |
WO2016151051A1 (en) * | 2015-03-23 | 2016-09-29 | Algipharma As | Use of alginate oligomers and cftr modulators in the treatment of conditions associated with cftr dysfunction |
WO2020025617A1 (en) | 2018-07-31 | 2020-02-06 | Algipharma As | Method for the qualitative and quantitative detection of alginate oligomers in body fluids |
WO2020254427A1 (en) | 2019-06-17 | 2020-12-24 | Algipharma As | Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense microstructure |
US11413306B2 (en) | 2015-10-06 | 2022-08-16 | Algipharma As | Alginate oligomers for the treatment or prevention of microbial overgrowth in the intestinal tract |
US11712448B2 (en) | 2013-12-20 | 2023-08-01 | Algipharma As | Use of alginate oligomers as blood anticoagulants |
US11992553B2 (en) | 2014-08-29 | 2024-05-28 | Algipharma As | Inhalable powder formulations of alginate oligomers |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9987235B2 (en) | 2013-08-01 | 2018-06-05 | Nicholas L. Abbott | Methods and compositions for modifying mucous membranes |
CA2934950A1 (en) * | 2013-12-23 | 2015-07-02 | Norwegian University Of Science And Technology | Uses of oligouronates in cancer treatment |
FR3024358B1 (en) * | 2014-08-01 | 2017-11-10 | Soc De Courtage Et De Diffusion Codif Int | COSMETIC COMPOSITIONS AND FOOD COMPONENTS NEURO-PROTECTIVE COMPRISING OLIGOALGINATE HAVING A POLYMERIZATION DEGREE OF 10 TO PREVENT AGING OF THE SKIN. |
CN115005447B (en) * | 2022-06-16 | 2024-02-06 | 青岛海关技术中心 | Application of oligoguluronic acid in preparation of anti-fatigue product |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1042379A (en) | 1956-12-20 | 1966-09-14 | Alexander Farkas | Improvements in or relating to polyuronides |
WO1988009794A1 (en) | 1987-06-02 | 1988-12-15 | Walsh William E | Cyclopolyglycuronic acid composition and its use |
EP0324720A1 (en) * | 1988-01-14 | 1989-07-19 | Warner-Lambert Company | Saccharide inhibition of dental plaque |
EP1714660A1 (en) * | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR7576M (en) * | 1968-03-27 | 1970-01-05 | ||
HU172831B (en) * | 1976-03-31 | 1978-12-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing complex compounds of oligo- and polygalacturonic acids with essential metal ions |
JPS6176413A (en) | 1984-09-21 | 1986-04-18 | Junzo Sunamoto | Production of liposome encapsulated with water-absorbing high polymer |
DD268865A1 (en) * | 1987-01-16 | 1989-06-14 | Adw Ddr | PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATORY |
JP2641472B2 (en) | 1988-01-30 | 1997-08-13 | 日本レダリー株式会社 | Infectious disease treatment |
US5459054A (en) | 1989-12-05 | 1995-10-17 | Neocrin Company | Cells encapsulated in alginate containing a high content of a- l- guluronic acid |
JPH05502863A (en) | 1989-12-05 | 1993-05-20 | トランセル・コーポレイション | Coating composition homologous guluronic acid-alginate for in vivo application and implantation and methods of use thereof |
WO1991011205A1 (en) | 1990-01-23 | 1991-08-08 | Trancel Corporation | Mannuronic acid containing alginate wound healing composition and method |
US5166137A (en) * | 1991-03-27 | 1992-11-24 | Nobipols Forskningsstiftelse | Guluronic acid polymers and use of same for inhibition of cytokine production |
US5952308A (en) * | 1991-07-29 | 1999-09-14 | Pola Chemical Industries Inc. | Mineral absorption promoting agent |
US5460957A (en) | 1992-04-28 | 1995-10-24 | Maruha Corporation | Calcium alginate oligosaccharide and method for producing the same from potassium or sodium alginate |
HU213872B (en) * | 1993-09-08 | 1997-11-28 | Mta Koezponti Kemiai Kutato In | Oligo- and polygalacturonate mixed complex, pharmaceutical and food compositions containing them, further process for preparing these compounds |
DE4330773A1 (en) * | 1993-09-10 | 1995-03-16 | Laevosan Gmbh & Co Kg | Blocking the attachment of germs to human cells |
JP2828391B2 (en) | 1993-10-29 | 1998-11-25 | 東燃株式会社 | Liposomes with oligosaccharides on the surface |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6140121A (en) | 1995-10-19 | 2000-10-31 | Advanced Reproduction Technologies, Inc. | Methods and compositions to improve germ cell and embryo survival and function |
JP3512553B2 (en) * | 1996-01-30 | 2004-03-29 | ポーラ化成工業株式会社 | Constipation inhibitor and composition containing it |
FR2747045B1 (en) | 1996-04-05 | 1998-06-26 | Hooreman Michel | NEW MEDICINE OPTIMIZING THE VISCOSITY OF MUCUSES AND IMPROVING THE FUNCTIONING OF THE INTESTIN |
NO305441B1 (en) | 1996-07-12 | 1999-05-31 | Norsk Hydro As | Use of G-block polysaccharides |
EP0963196B1 (en) | 1996-09-27 | 2005-01-19 | Jagotec Ag | Hyaluronic drug delivery system |
NO305033B1 (en) * | 1997-05-09 | 1999-03-22 | Algipharma As | Process for the preparation of uric acid blocks from alginate |
US6339075B1 (en) * | 1997-06-30 | 2002-01-15 | The University Of British Columbia | Use of dextran and other polysaccharides to improve mucus clearance |
KR100219918B1 (en) | 1997-07-03 | 1999-09-01 | 김윤 | Composition for colon specific drug delivery |
JP3932679B2 (en) | 1998-07-21 | 2007-06-20 | セイコーエプソン株式会社 | Production method of polyguluronic acid |
US6290987B1 (en) | 1998-09-27 | 2001-09-18 | Generex Pharmaceuticals, Inc. | Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids |
US20040224922A1 (en) * | 1999-08-26 | 2004-11-11 | Malcolm King | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
EP1212047A2 (en) * | 1999-08-26 | 2002-06-12 | The Governors Of The University Of Alberta | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
US7785625B2 (en) * | 2000-01-14 | 2010-08-31 | Lg Life Sciences, Limited | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
KR100501584B1 (en) * | 2000-02-03 | 2005-07-18 | (주)케이비피 | Process for preparing low molecular polymannuronate, a novel use thereof as controller of serum lipids, and functional foods and health-aid foods comprising the same |
DE10006989A1 (en) * | 2000-02-16 | 2001-08-23 | Nutricia Nv | Pharmaceutical or dietetic preparation for preventing cellular adhesion of pathogens, e.g. in treatment of infections, comprising carbohydrate having double bond-containing terminal uronic acid unit |
PL202918B1 (en) | 2000-03-07 | 2009-08-31 | Rush Presbyterian St Luke | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
WO2001072278A2 (en) | 2000-03-30 | 2001-10-04 | Generex Pharmaceuticals Inc. | Method for administering insulin to the buccal region |
DE10019076A1 (en) * | 2000-04-06 | 2001-10-18 | Lang Christine | Use of polygalacturonides as food additives |
JP2002338493A (en) | 2000-10-23 | 2002-11-27 | Genaera Corp | Mucin synthesis inhibitor |
DE10057976B4 (en) | 2000-11-22 | 2005-02-03 | Südzucker AG Mannheim/Ochsenfurt | Process for the preparation of pectin hydrolysis products |
US6440314B1 (en) * | 2001-01-03 | 2002-08-27 | Vulcan Chemical Technologies, Inc. | Method for destroying chlorite in solution |
ITMI20010347A1 (en) | 2001-02-21 | 2002-08-21 | Grisotech S A | IMMUNOGLOBULIN AND POLYSACCHARID COMPLEXES FOR ORAL ABSORPTION ETRANS-MUCOSAL |
US6610331B1 (en) | 2002-05-30 | 2003-08-26 | Scott M. Sweazy | Fertility kit |
JP2005145885A (en) | 2003-11-14 | 2005-06-09 | Japan Science & Technology Agency | Immunologic mechanism activator comprising alginic acid oligomer |
CA2558835C (en) | 2004-03-12 | 2011-06-28 | Biodel, Inc. | Rapid acting drug delivery compositions |
US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
JP2006028041A (en) | 2004-07-13 | 2006-02-02 | Ltt Bio-Pharma Co Ltd | Nucleic acid-containing nano particle |
US7621036B2 (en) | 2005-06-21 | 2009-11-24 | Cardiomems, Inc. | Method of manufacturing implantable wireless sensor for in vivo pressure measurement |
EP1745705A1 (en) | 2005-07-20 | 2007-01-24 | N.V. Nutricia | Process for preparing uronic acid oligosaccharides by extrusion |
GB2430881B (en) | 2005-10-06 | 2010-10-13 | Ntnu Technology Transfer As | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
US20090214660A1 (en) | 2005-10-21 | 2009-08-27 | Living Cell Products Pty Limited | Encapsulation system |
GB0707096D0 (en) | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
WO2008137114A1 (en) | 2007-05-04 | 2008-11-13 | University Of Hawai'i | Methods and compositions for targeted delivery of gene therapeutic vectors |
WO2009142892A1 (en) | 2008-05-19 | 2009-11-26 | The University Of North Carolina At Chapel Hill | Methods and compositions comprising novel cationic lipids |
-
2005
- 2005-10-06 GB GB0520375A patent/GB2430881B/en not_active Expired - Fee Related
-
2006
- 2006-10-06 WO PCT/GB2006/003732 patent/WO2007039760A2/en active Application Filing
- 2006-10-06 DK DK06794671.5T patent/DK1942938T3/en active
- 2006-10-06 EP EP18179968.5A patent/EP3403657B1/en active Active
- 2006-10-06 EA EA200801033A patent/EA015436B1/en unknown
- 2006-10-06 BR BRPI0616982A patent/BRPI0616982B8/en not_active IP Right Cessation
- 2006-10-06 ES ES06794671T patent/ES2390974T3/en active Active
- 2006-10-06 EP EP06794671A patent/EP1942938B1/en active Active
- 2006-10-06 PL PL18179968T patent/PL3403657T3/en unknown
- 2006-10-06 DK DK10189506.8T patent/DK2311497T3/en active
- 2006-10-06 KR KR1020087010474A patent/KR101144576B1/en active IP Right Grant
- 2006-10-06 CA CA2624568A patent/CA2624568C/en active Active
- 2006-10-06 CN CN2006800460615A patent/CN101325973B/en active Active
- 2006-10-06 WO PCT/GB2006/003720 patent/WO2007039754A1/en active Application Filing
- 2006-10-06 JP JP2008534075A patent/JP5313677B2/en active Active
- 2006-10-06 ES ES18179968T patent/ES2907875T3/en active Active
- 2006-10-06 ES ES10189506.8T patent/ES2688971T3/en active Active
- 2006-10-06 US US12/089,530 patent/US8673878B2/en active Active
- 2006-10-06 US US12/089,529 patent/US8754063B2/en active Active
- 2006-10-06 DK DK18179968.5T patent/DK3403657T3/en active
- 2006-10-06 EP EP10189506.8A patent/EP2311497B1/en active Active
- 2006-10-06 AU AU2006298544A patent/AU2006298544B2/en active Active
- 2006-10-06 EP EP06794683A patent/EP1954315A2/en not_active Withdrawn
-
2009
- 2009-05-21 HK HK09104636.3A patent/HK1125855A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1042379A (en) | 1956-12-20 | 1966-09-14 | Alexander Farkas | Improvements in or relating to polyuronides |
WO1988009794A1 (en) | 1987-06-02 | 1988-12-15 | Walsh William E | Cyclopolyglycuronic acid composition and its use |
EP0324720A1 (en) * | 1988-01-14 | 1989-07-19 | Warner-Lambert Company | Saccharide inhibition of dental plaque |
EP1714660A1 (en) * | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8754063B2 (en) | 2005-10-06 | 2014-06-17 | NTNU Technology Transfers AS | Use of oligouronates for treating mucus hyperviscosity |
US8673878B2 (en) | 2005-10-06 | 2014-03-18 | Ntnu Technology Transfer As | Mucosal treatment |
EA018776B1 (en) * | 2007-04-12 | 2013-10-30 | ЭнТиЭнЮ ТЕКНОЛОДЖИ ТРАНСФЕР АС | Pharmaceutical composition comprising oligo-guluronate or galacturonate, methods of treatment using same, use thereof and spray applicator comprising same |
US8841279B2 (en) | 2007-04-12 | 2014-09-23 | Norwegian University Of Science And Technology | Oligo-guluronate and galacturonate compositions |
EP2500025A1 (en) | 2007-04-12 | 2012-09-19 | NTNU Technology Transfer AS | Oligo-guluronate and galacturonate compositions |
WO2008125828A2 (en) * | 2007-04-12 | 2008-10-23 | Ntnu Technology Transfer As | Oligo-guluronate and galacturonate compositions |
AU2008237710B2 (en) * | 2007-04-12 | 2014-02-06 | Ntnu Technology Transfer As | Oligo-guluronate and galacturonate compositions |
WO2008125828A3 (en) * | 2007-04-12 | 2009-06-04 | Ntnu Technology Transfer As | Oligo-guluronate and galacturonate compositions |
US9877983B2 (en) | 2007-11-27 | 2018-01-30 | Algipharma As | Use of alginate oligomers in combating biofilms |
US10624920B2 (en) | 2007-11-27 | 2020-04-21 | Algipharma As | Use of alginate oligomers in combating biofilms |
US8680072B2 (en) | 2007-11-27 | 2014-03-25 | Algipharma As | Use of alginate oligomers in combating biofilms |
US8987215B2 (en) | 2009-03-23 | 2015-03-24 | Ntnu Technology Transfer As | Composition for use in gene therapy |
US8529890B2 (en) | 2009-03-23 | 2013-09-10 | Ntnu Technology Transfer As | Composition for the administration of polymeric drugs |
US8815831B2 (en) | 2009-06-03 | 2014-08-26 | Algipharma As | Treatment of Acinetobacter with alginate oligomers and antibiotics |
WO2010139957A1 (en) | 2009-06-03 | 2010-12-09 | Algipharma Ipr As | Alginate oligomers for use in overcoming multidrug resistance in bacteria |
WO2010139959A2 (en) | 2009-06-03 | 2010-12-09 | Algipharma Ipr As | Alginate oligomers for the inhibition of microbial adherence to surfaces |
US9018158B2 (en) | 2009-06-03 | 2015-04-28 | Algipharma As | Alginate oligomers for use in overcoming multidrug resistance in bacteria |
US9801901B2 (en) | 2009-06-03 | 2017-10-31 | Algipharma As | Alginate oligomers for use in overcoming multidrug resistance in bacteria |
WO2010139958A1 (en) | 2009-06-03 | 2010-12-09 | Algipharma Ipr As | Anti-microbial alginate oligomers |
WO2010139956A1 (en) | 2009-06-03 | 2010-12-09 | Algipharma Ipr As | Treatment of acinetobacter with alginate oligomers and antibiotics |
WO2013038197A1 (en) | 2011-09-15 | 2013-03-21 | Algipharma As | Use of alginate oligomers to enhance the effects of antifungal agents |
US11712448B2 (en) | 2013-12-20 | 2023-08-01 | Algipharma As | Use of alginate oligomers as blood anticoagulants |
WO2015128495A1 (en) * | 2014-02-28 | 2015-09-03 | Algipharma As | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function |
US11992553B2 (en) | 2014-08-29 | 2024-05-28 | Algipharma As | Inhalable powder formulations of alginate oligomers |
AU2016236172B2 (en) * | 2015-03-23 | 2021-07-01 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfunction |
US10751363B2 (en) | 2015-03-23 | 2020-08-25 | Algipharma As | Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction |
WO2016151051A1 (en) * | 2015-03-23 | 2016-09-29 | Algipharma As | Use of alginate oligomers and cftr modulators in the treatment of conditions associated with cftr dysfunction |
US11413306B2 (en) | 2015-10-06 | 2022-08-16 | Algipharma As | Alginate oligomers for the treatment or prevention of microbial overgrowth in the intestinal tract |
US11385174B2 (en) | 2018-07-31 | 2022-07-12 | Algipharma As | Method for the qualitative and quantitative detection of alginate oligomers in body fluids |
WO2020025617A1 (en) | 2018-07-31 | 2020-02-06 | Algipharma As | Method for the qualitative and quantitative detection of alginate oligomers in body fluids |
WO2020254427A1 (en) | 2019-06-17 | 2020-12-24 | Algipharma As | Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense microstructure |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8754063B2 (en) | Use of oligouronates for treating mucus hyperviscosity | |
US10729786B2 (en) | Mucus penetrating gene carriers | |
KR101336459B1 (en) | Oligo-guluronate and galacturonate compositions | |
EP1407776B1 (en) | A pharmaceutical colloidal preparation comprising hyaluronic acid biopolymers useful in the treatment of respiratory diseases | |
MX2008004472A (en) | Use of oligouronates for treating mucus hyperviscosity | |
CN117693352A (en) | Glutathione C4 against airway diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680046061.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2624568 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/004472 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008534075 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087010474 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3741/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006794671 Country of ref document: EP Ref document number: 2006298544 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200801033 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2006298544 Country of ref document: AU Date of ref document: 20061006 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006298544 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006794671 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12089529 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0616982 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080407 |